Concomitant use of strong CYP3A4 or P-glycoprotein inducers…
Concomitant use of strong CYP3A4 or P-glycoprotein inducers with factor Xa inhibitors (DOACs) primarily increases risk for: Warfarin-like INR elevation Accumulation of inactive metabolites Reduced anticoagulant effectiveness Excessive platelet inhibition